Neladenoson bialanate
Also known as: BAY 1067197, BAY 1067197 bialanate, BAY-1067197, neladenoson bialanate
Source Neladenoson bialanate at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Neladenoson bialanate is a pro‑drug of the selective A1 adenosine receptor agonist neladenoson, investigated for the treatment of chronic heart failure. Development was discontinued after Phase II studies.
Mechanism of Action
Selective activation of adenosine A1 receptors, producing negative chronotropic and dromotropic effects and cardioprotective signaling pathways.
Routes of Administration
Goals & Uses
- Chronic heart failure with reduced ejection fraction (HFrEF)CardiovascularModerate
- CardioprotectionCardiovascularLow
- Heart rate reductionCardiovascularModerate
- Chronic heart failureCardiovascularModerate
- Heart failure with preserved ejection fraction (HFpEF)CardiovascularLow
Contraindications
- Second‑ or third‑degree AV blockCardiac ConductionHigh
- Severe bradycardiaCardiacHigh
- Known hypersensitivity to neladenoson or excipientsAllergyHigh
- Second or third degree AV blockCardiac ConductionHigh
Adverse Effects
- HypotensionCardiovascularCommonLow blood pressure
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- AV conduction prolongationCardiovascularUncommon
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
- BradycardiaCardiovascularCommon
Drug Interactions
- Calcium channel blockers (non-dihydropyridine)Moderate
- Beta‑blockersModerate
- Beta-blockersModerate
- DigoxinModerate
- Methylxanthines (e.g., theophylline, caffeine)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
- Severe renal impairment (eGFR <30 mL/min)RenalRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization granted.
- United StatesInvestigationalPhase II completed; development discontinued.
- United KingdomInvestigationalNo approval; investigational use only in clinical trial context.
Completed Phase II trials in heart failure; development halted; never received marketing authorization.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Neladenoson bialanate?
Neladenoson bialanate is a pro‑drug of the selective A1 adenosine receptor agonist neladenoson, investigated for the treatment of chronic heart failure. Development was discontinued after Phase II studies.
What is Neladenoson bialanate used for?
Neladenoson bialanate is educationally associated with: Chronic heart failure with reduced ejection fraction (HFrEF), Cardioprotection, Heart rate reduction, Chronic heart failure, Heart failure with preserved ejection fraction (HFpEF). Educational only — not medical advice.
How is Neladenoson bialanate administered?
Recorded routes of administration: Oral.
What are the potential side effects of Neladenoson bialanate?
Reported adverse effects include: Hypotension, Nausea, AV conduction prolongation, Dizziness, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Neladenoson bialanate?
Recorded contraindications: Second‑ or third‑degree AV block, Severe bradycardia, Known hypersensitivity to neladenoson or excipients, Second or third degree AV block. Consult a qualified clinician before use.